MX2018000104A - Indicador terapeutico atomico. - Google Patents

Indicador terapeutico atomico.

Info

Publication number
MX2018000104A
MX2018000104A MX2018000104A MX2018000104A MX2018000104A MX 2018000104 A MX2018000104 A MX 2018000104A MX 2018000104 A MX2018000104 A MX 2018000104A MX 2018000104 A MX2018000104 A MX 2018000104A MX 2018000104 A MX2018000104 A MX 2018000104A
Authority
MX
Mexico
Prior art keywords
cancer
ati
hmrs
reoccur
tumour
Prior art date
Application number
MX2018000104A
Other languages
English (en)
Inventor
L Gabor Miklos George
Original Assignee
Atomic Oncology Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015902706A external-priority patent/AU2015902706A0/en
Application filed by Atomic Oncology Pty Ltd filed Critical Atomic Oncology Pty Ltd
Publication of MX2018000104A publication Critical patent/MX2018000104A/es

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
    • G01N27/64—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode using wave or particle radiation to ionise a gas, e.g. in an ionisation chamber
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T17/00—Three dimensional [3D] modelling, e.g. data description of 3D objects
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/103—Treatment planning systems
    • A61N5/1039—Treatment planning systems using functional images, e.g. PET or MRI
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Primary Health Care (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Software Systems (AREA)
  • Electrochemistry (AREA)
  • Computer Graphics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La presente invención se refiere a la generación de un indicador terapéutico atómico (ATI) para una muestra de prueba por la cuantificación de manganeso; en vóxeles de una región 3D de la muestra, en donde la región 3D se define topográficamente por coordenadas X'xY'xZ. El ATI se utiliza para evaluar la radio-sensibilidad, es decir, sensibilidad o resistencia al tratamiento con radiación, de un cáncer, es decir, un tumor/neoplasma. En una modalidad preferida, la presente invención se refiere a un método para generar el ATI, evaluar la radio-sensibilidad de un tumor/neoplasma con base en el ATI, y con base en la evaluación, ya sea tratar o no tratar el tumor con radiación. La presente invención también se refiere a un método para determinar si es probable que un cáncer re-ocurra después del tratamiento con radiación que comprende cuantificar el nivel de manganeso en vóxeles de una región 3D de una muestra de prueba del cáncer y determinar la frecuencia de las regiones altas metalómicas (HMR) en el cáncer, en donde una alta frecuencia de HMR es indicativa que es probable que el cáncer re-ocurra y una baja frecuencia de HMR es indicativa que es poco probable que el cáncer reocurra; y métodos asociados de tratamiento. La invención se refiere adicionalmente a un método para determinar la radio-sensibilidad de un melanoma, el método que comprende determinar el nivel de melanina en una muestra de prueba del melanoma, en donde a menor es el nivel de melanina más sensible es el melanoma a la radiación y a mayor es el nivel de melanina más resistente es el melanoma a la radiación; y métodos asociados de tratamiento.
MX2018000104A 2015-07-09 2016-07-11 Indicador terapeutico atomico. MX2018000104A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015902706A AU2015902706A0 (en) 2015-07-09 Atomic therapeutic indicator
PCT/AU2016/050603 WO2017004684A1 (en) 2015-07-09 2016-07-11 Atomic therapeutic indicator

Publications (1)

Publication Number Publication Date
MX2018000104A true MX2018000104A (es) 2018-06-20

Family

ID=57684750

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000104A MX2018000104A (es) 2015-07-09 2016-07-11 Indicador terapeutico atomico.

Country Status (10)

Country Link
US (1) US10254284B2 (es)
EP (1) EP3320521B1 (es)
JP (1) JP6603802B2 (es)
KR (1) KR102046265B1 (es)
CN (1) CN108027982A (es)
BR (1) BR112018000206A2 (es)
CA (1) CA2991246C (es)
ES (1) ES2781876T3 (es)
MX (1) MX2018000104A (es)
WO (1) WO2017004684A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016222299B1 (en) 2015-07-09 2016-11-03 Atomic Oncology Pty Ltd Atomic Therapeutic Indicator
CN110399649B (zh) * 2019-07-03 2023-05-30 中国石油天然气集团有限公司 一种基于成岩指示元素的变质岩量化识别方法
US11415582B2 (en) 2019-10-24 2022-08-16 King Fahd University Of Petroleum And Minerals Method for detecting and treating colon cancer by measuring heavy metal concentrations
CN111241086B (zh) * 2020-01-17 2021-08-31 甘肃省卫生健康统计信息中心(西北人口信息中心) 一种基于医疗大数据的数据质量改进方法及系统
CN111624191A (zh) * 2020-03-02 2020-09-04 北京理工大学 一种离在体通用的脑肿瘤活检和边界确定装置
JP2022131579A (ja) 2021-02-26 2022-09-07 キオクシア株式会社 分析装置および分析方法
CN115372604B (zh) * 2022-07-07 2023-03-28 山东第一医科大学附属省立医院(山东省立医院) 一种用于预测肿瘤患者免疫治疗疗效的标志物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008007A (en) 1997-01-31 1999-12-28 Oncotech, Inc. Radiation resistance assay for predicting treatment response and clinical outcome
US8849579B2 (en) * 2006-10-02 2014-09-30 3D Signatures Inc. Methods of detecting and monitoring cancer using 3D analysis of centromeres
RU2545097C2 (ru) * 2009-10-06 2015-03-27 Конинклейке Филипс Электроникс Н.В. Ретроспективное вычисление дозы облучения и усовершенствованное планирование лечения
JPWO2011155168A1 (ja) * 2010-06-07 2013-08-01 パナソニック株式会社 組織悪性腫瘍検出方法、組織悪性腫瘍検出装置
JP2014504149A (ja) * 2010-10-28 2014-02-20 ヴァージニア コモンウェルス ユニバーシティ 治療と併用する癌画像診断：セラノスティックス
AU2014321355B2 (en) * 2013-09-20 2019-10-10 The Regents Of The University Of Michigan Compositions and methods for the analysis of radiosensitivity
WO2015047226A1 (en) 2013-09-24 2015-04-02 Halliburton Energy Services, Inc. Evaluation of downhole electric components by monitoring umbilical health and operation
AU2016222299B1 (en) 2015-07-09 2016-11-03 Atomic Oncology Pty Ltd Atomic Therapeutic Indicator

Also Published As

Publication number Publication date
KR102046265B1 (ko) 2019-11-18
WO2017004684A1 (en) 2017-01-12
EP3320521A1 (en) 2018-05-16
CA2991246A1 (en) 2017-01-12
US20180143197A1 (en) 2018-05-24
ES2781876T3 (es) 2020-09-08
CA2991246C (en) 2020-02-25
EP3320521B1 (en) 2020-03-25
JP2018529975A (ja) 2018-10-11
CN108027982A (zh) 2018-05-11
JP6603802B2 (ja) 2019-11-06
BR112018000206A2 (pt) 2018-09-04
EP3320521A4 (en) 2019-01-23
US10254284B2 (en) 2019-04-09
KR20180031702A (ko) 2018-03-28

Similar Documents

Publication Publication Date Title
MX2018000104A (es) Indicador terapeutico atomico.
PH12018500902A1 (en) Point mutations in trk inhibitor-resistant cancer and methods relating to the same
PH12017502200A1 (en) Methods of diagnosing and treating cancer
AU2018260845A1 (en) Evaluation and treatment of bradykinin-mediated disorders
GB2552267A (en) Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
MX2017005751A (es) Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
TN2013000358A1 (en) Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
GB2547838A (en) Method and system for improved classification of constituent materials
MX2018006781A (es) Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap.
WO2015172085A3 (en) Biomarkers for response to pi3k inhibitors
EP4282405A3 (en) Detection of cancer biomarkers using nanoparticles
MX2018008169A (es) Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
MX368099B (es) Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
WO2015131151A3 (en) Method and apparatus for determining markers of health by analysis of blood
MX2016013910A (es) Tratamiento del cancer.
WO2018097614A3 (ko) 유방암 환자의 화학치료 유용성 예측 방법
WO2015092046A3 (en) Prostate cancer biomarkers
Zhang et al. Elevated serum ferritin levels in patients with hematologic malignancies
DE112012001274A5 (de) Verfahren und Vorrichtung zur Untersuchung der röntgenografischen Eigenschaften von Proben
WO2015166353A3 (en) Early detection of preeclampsia
MX2019003731A (es) Métodos para diagnosticar y tratar el cáncer de próstata metastásico resistente a la castración resistente o sensible al tratamiento con acetato de abiraterona-glucocorticoide.
WO2019178606A8 (en) Methods for personalized detection of the recurrence of cancer or metastasis and/or evaluation of treatment response
Huang et al. Value of positive lymph node ratio for predicting postoperative distant metastasis and prognosis in esophageal squamous cell carcinoma
MX2022015457A (es) Deteccion temprana de carcinoma hepatocelular.

Legal Events

Date Code Title Description
FG Grant or registration